MYGN
T2Myriad Genetics, Inc.
Genomics '25: Molecular Diagnostics & Clinical GenomicsMedTech Long '26: Diagnostics & Early Detection
OverviewMyriad Genetics, Inc. develops molecular diagnostic tests across oncology, women's health, and mental health. Oncology tests help guide cancer risk and treatmen
Myriad Genetics, Inc. develops molecular diagnostic tests across oncology, women's health, and mental health. Oncology tests help guide cancer risk and treatment, women's health screens for genetic conditions, and mental health aids medication selection. The Cancer Care Continuum generates ~60% of revenue, Prenatal Health ~21%, and Mental Health ~19%. The company primarily sells to community oncologists and other healthcare providers.
- What They Do (Plain English & Analogies)
- Myriad Genetics is like a detective agency for your DNA, helping doctors and patients understand their genetic information to make better healthcare decisions. They offer specialized genetic tests primarily in three areas: first, for cancer, to assess a person's risk of developing certain cancers, guide treatment for existing cancers, or detect minimal residual disease (MRD) after treatment; second, for women's health, especially during pregnancy, to screen for genetic conditions in the baby or the parents; and third, for mental health, to help doctors choose the most effective medications for conditions like depression or anxiety based on an individual's genetic makeup. They provide detailed reports that translate complex genetic information into clear, actionable insights for healthcare providers.
- Very Brief History
- Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. The company initially built its reputation and core business in hereditary cancer testing, notably with BRCA-related tests. Over the years, it has expanded its portfolio through acquisitions (like Assurex Health in 2016 and Counsyl in 2018) and internal development into women's health, mental health, and oncology companion diagnostics, evolving into a molecular diagnostics and precision medicine company.
- "Street Stereotype"
- Myriad Genetics is generally perceived as a mature but still relevant clinical genomics company. While it has a broad portfolio spanning hereditary cancer, tumor profiling, reproductive health, pharmacogenomics, and molecular residual disease (MRD) testing, some investors and analysts might view its growth and 'purity' in high-growth segments as potentially lower compared to some newer, more specialized players in the genomics space. The company is seen as having steady margin improvements and benefiting from expanding screening guidelines for high-risk individuals, sustaining solid structural growth.
- Subsidiaries On Linked In*
- Assurex Health Ltd. — Operates as Myriad Neuroscience for GeneSight
- Myriad GmbH — Germany-based subsidiary
- Myriad Genetics GK — Japan-based subsidiary
- Myriad Genetics Australia PTY LTD — Australia-based subsidiary
- Myriad Genetics B.V. — Netherlands-based subsidiary
- Myriad Women's Health Inc. — US-based subsidiary
- Gateway Genomics LLC — US-based subsidiary
- Privatklinik Dr Robert Schindlbeck GmbH & Co KG — Germany-based subsidiary
- Customer Sectors & Example Clients
- Myriad Genetics primarily serves the healthcare sector. Their customers include oncologists, obstetricians/gynecologists, psychiatrists, and other medical specialists within community oncology practices, hospitals, and broader provider networks. While specific client company names are not disclosed, their business model indicates that their clients are healthcare providers and institutions rather than direct-to-consumer sales.
- New Customers / Segments They'Re Targeting
- Myriad Genetics is actively targeting new customer segments and expanding its reach. In the Cancer Care Continuum, they are making significant investments to expand their commercial capabilities and focus on community oncology, where over 75% of cancer care in the United States occurs, particularly for their new Precise MRD test. They are also driving strong volume growth in the unaffected population for hereditary cancer testing. In prenatal health, they are focused on reactivating accounts, expanding access, and winning new customers, supported by a newly deployed prenatal-focused sales team and the upcoming FirstGene test, which is expected to expand the overall prenatal testing market by addressing situations where male partners are unavailable for testing. For mental health, they continue to expand their GeneSight ordering provider base, reaching a record high of over 39,000 ordering clinicians in Q1 2026.
- Supply Chain And Sourcing Geographies
- Myriad Genetics operates manufacturing facilities primarily in the United States. Their operational footprint includes facilities in Salt Lake City, Utah (headquarters), South San Francisco, California, Mason, Ohio, and Austin, Texas, which house laboratory, manufacturing, and commercial operations. The company's value proposition relies on clinical evidence, bioinformatics, and specialist sales execution, implying that the core 'sourcing' is often intellectual property, genetic samples, and highly skilled labor within these established laboratory and R&D hubs.
- Sales Geographies And Expansion Plans
- Myriad Genetics primarily sells its products in the United States, which represents the heaviest portion of its business. They also have a more limited international presence through direct operations and partners in various regions, including parts of Europe (e.g., Switzerland, Ireland, UK, Germany, Italy, Spain, Portugal, Greece, Turkey, Estonia, Israel, Egypt), Latin America (e.g., Chile, Mexico, Panama, Costa Rica, Guatemala, Paraguay, Peru, Uruguay), and Asia Pacific (e.g., Hong Kong, Singapore, South Korea, Taiwan, Thailand, Philippines, Japan, Australia). Domestically, they are expanding commercial testing for Precise MRD for breast cancer in Q3 2026 beyond their current select community practices. They are also moving up the launch of Precise MRD for colorectal and renal cancer to a select set of customers into Q3 2026. The company has expanded its sales team by over 100 account executives, particularly in oncology, to increase its market share in the U.S.
- How Key Themes May Help/Hurt
- Myriad Genetics is well-positioned to benefit from the 'MedTech Long '26: Diagnostics & Early Detection' theme due to its strategic prioritization and significant investments in the Cancer Care Continuum. The alpha launch and planned expansion of Precise MRD for various cancers, along with the upcoming AI-enhanced Prolaris prostate cancer test, directly contribute to the theme's focus on early detection and advanced diagnostics. The company's emphasis on genetic risk assessment and targeted precision therapies, coupled with expanding screening guidelines, sustains structural growth within this theme. The integration of AI in the Prolaris test also reflects the broader industry trend of accelerating technological advancements in genomics and AI driving diagnostic development. However, Myriad may be hurt by persistent reimbursement pressures and evolving payer policies, including potential average selling price (ASP) declines for novel tests like MRD, which could impact profitability and market uptake. Intensifying competition from both established players and new entrants in the diagnostics and early detection space could also lead to pricing pressures and increased commercialization costs.
3 Main Long-Term Bull Details
- Strategic Focus and Growth in Cancer Care Continuum: Myriad's strategic prioritization and significant investments in the Cancer Care Continuum, including expanded commercial capabilities and increased R&D, are yielding strong results, with hereditary cancer testing volumes growing 14% year-over-year (16% in the unaffected population). This focus, combined with new product launches like Precise MRD and the AI-enhanced Prolaris, positions the company for continued share gain and profitable growth in a large, underpenetrated market.
- Robust and Differentiated Product Pipeline: The company has a pipeline of innovative and highly differentiated products, including the alpha launch of Precise MRD for breast cancer (with planned expansion to colorectal and renal), the upcoming AI-enhanced Prolaris prostate cancer test, and the unique FirstGene prenatal test. These new offerings are designed to provide significant clinical value, expand market opportunities, and drive future growth.
- Improving Commercial Execution and Profitability Management: Myriad is committed to profitable growth, maintaining solid gross margins (68.7% in Q1 2026) while making strategic investments. The expansion of its sales team by over 100 account executives, along with enhanced demand generation and launch execution strategies, is expected to accelerate growth and improve financial performance in the coming quarters. The GeneSight business also continues to deliver strong performance and improving profitability, providing a stable foundation.
3 Main Long-Term Bear Details
- Persistent Reimbursement Pressures and ASP Headwinds: Myriad generally anticipates 'modest headwinds to ASPs over the longer term' across its portfolio. Evolving payer policies and the need for extensive evidence generation for novel tests like MRD could impact profitability and market uptake, as highlighted by the broader industry trend.
- Challenges in Prenatal Business: The prenatal health segment experienced a significant 15% year-over-year revenue decline in Q1 2026, despite signs of stabilization. While the FirstGene launch is a positive catalyst, any delays in its adoption or continued underperformance in the broader prenatal portfolio could impact the expected return to growth and full-year guidance.
- Profitability Impact from Growth Investments: Accelerated commercial growth investments led to an adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09 in Q1 2026, falling below near breakeven commentary. While strategic, the ramp-up of over 100 new sales representatives will take several quarters to reach peak productivity, potentially delaying the positive impact on profitability and revenue acceleration in the near term.
- Competitors And Differentiation
- Myriad Genetics faces competition from both established players and new entrants in its various segments. Key competitors include Exact Sciences, Natera, Veracyte, Labcorp, Quest Diagnostics, and Tempus AI. Myriad differentiates itself through: its MyRisk hereditary cancer test, which with 63 genes is considered the 'most relevant current' panel for hereditary cancer testing; its Precise MRD test, which offers high sensitivity (detecting disease down to 1 part per million) and the ability to detect recurrence meaningfully earlier than standard imaging; the AI-enhanced Prolaris prostate cancer test, which combines AI, biomarker, germline, and genomic insights in a single offering; GeneSight, which holds the leading market share in the mental health testing market; and FirstGene, which is highlighted as the first and only screen to simultaneously test for patient carrier status, fetal single gene, fetal chromosome, and fetal RHD status, delivered in a single integrated report, with an industry-leading 8-week gestational age and 14-day turnaround time.
- Recent Performance & What The Market'S Focused On
- Myriad Genetics reported mixed financial results for Q1 2026, with revenue of $200.4 million, representing 2% year-over-year growth, but missing analyst consensus estimates. The company posted an adjusted EPS loss of $0.09 and an adjusted EBITDA loss of $4.5 million, which was below its near breakeven commentary, primarily due to accelerated commercial growth investments. Hereditary cancer testing volume grew strongly at 14% year-over-year (16% in the unaffected population), and GeneSight revenue increased 24% year-over-year on 7% volume growth. However, prenatal health revenue declined 15% year-over-year. The market is focused on Myriad's reaffirmed full-year 2026 financial guidance, which anticipates sequential revenue growth in the low single digits in Q2, accelerating through the remaining quarters of the year. Key areas of market focus include the successful ramp-up of the expanded commercial team, the initial market adoption and customer feedback for the newly launched Precise MRD and AI-enhanced Prolaris tests, and the full commercial launch of the FirstGene prenatal test in the second half of 2026. Investors are also closely watching the company's ability to manage operating expenses and translate its strategic investments into improved profitability.
- Revenue Segments And Estimated Mix
- Cancer Care Continuum — Mix: ~60%; Source: Q1 2026 transcript: $120.2 million out of $200.4 million total revenue; Trend: Up 4% year-over-year; hereditary cancer testing volume grew 14%
- Prenatal Health — Mix: ~21%; Source: Q1 2026 transcript: $41.9 million out of $200.4 million total revenue; Trend: Down 15% year-over-year; seeing signs of stabilization with quarter-over-quarter volume growth in Q1
- Mental Health — Mix: ~19%; Source: Q1 2026 transcript: $38.3 million out of $200.4 million total revenue; Trend: Up 24% year-over-year on 7% volume growth
- Product Brands
- MyRisk Hereditary Cancer test
- BRACAnalysis CDx
- MyChoice CDx
- Prolaris Prostate Cancer Prognostic test
- AI-enhanced Prolaris
- EndoPredict Breast Cancer Prognostic test
- Precise Tumor Molecular Profile test
- Precise MRD
- Prequel Prenatal Screen
- Foresight Carrier Screen
- Foresight Universal Plus
- SneakPeek Early Gender DNA test
- FirstGene
- GeneSight Psychotropic Mental Health Medication test
Bull / Bear DetailsMyriad Genetics is positioned for accelerated profitable growth, driven by its strategic prioritization and significant investment in the Cancer Care Continuum.
Thesis
Myriad Genetics is positioned for accelerated profitable growth, driven by its strategic prioritization and significant investment in the Cancer Care Continuum. Strong hereditary cancer testing growth, the expanded availability of Precise MRD, and the recent launches of AI-enhanced Prolaris and differentiated FirstGene are key catalysts. While Q1 profitability was impacted by investments and prenatal business faced near-term headwinds, a focused commercial expansion and improving GeneSight reimbursement underpin confidence in H2 2026 acceleration. (July 27, 2026)
Bull case
Myriad's strategic focus on the Cancer Care Continuum is yielding strong results, with hereditary cancer testing volumes growing 14% year-over-year, including a 16% increase in the unaffected population. This segment remains the company's 'profit engine,' providing a stable foundation and funding for strategic investments in new product development and commercial expansion.
The company is executing on a robust product pipeline, with the alpha launch of Precise MRD for breast cancer showing encouraging early feedback and planned expansion to colorectal and renal cancers in Q3 2026. The AI-enhanced Prolaris prostate cancer test launched in June, and the highly differentiated FirstGene prenatal test is on track for a full commercial launch in H2 2026, offering significant market expansion opportunities.
The mental health business, GeneSight, continues its strong performance, delivering 24% year-over-year revenue growth on 7% volume growth in Q1 2026. This is supported by improved reimbursement trends, favorable biomarker legislation, and a record high of over 39,000 ordering clinicians. The expansion of the commercial team by over 100 account executives is expected to accelerate growth across the portfolio in the second half of the year.
Bear case
Despite management's confidence, the prenatal health segment experienced a significant 15% year-over-year revenue decline in Q1 2026. While FirstGene's launch is a positive catalyst, the segment's ability to consistently return to positive growth and regain lost market share remains a key challenge, potentially impacting the company's full-year revenue guidance.
Accelerated commercial growth investments led to an adjusted EBITDA loss of $5 million and an adjusted EPS loss of $0.09 in Q1 2026, falling below near breakeven commentary. The ramp-up of over 100 new sales representatives will take several quarters to reach peak productivity, potentially delaying the expected positive impact on profitability and revenue acceleration in the near term.
Myriad continues to anticipate modest headwinds to average selling prices (ASPs) over the longer term. This, combined with intensifying competition across its segments, could put pressure on gross margins and overall profitability, particularly as new tests like Precise MRD await broader reimbursement and market adoption.
Bull / Bear Case
- Bear Case
- Despite management's confidence, the prenatal health segment experienced a significant 15% year-over-year revenue decline in Q1 2026. While the FirstGene launch is a positive catalyst, the segment's ability to consistently return to positive growth and regain lost market share remains a key challenge, potentially impacting the company's full-year revenue guidance. Accelerated commercial growth investments led to an adjusted EBITDA loss of $5 million and an adjusted EPS loss of $0.09 in Q1 2026, falling below near breakeven commentary. The ramp-up of over 100 new sales representatives will take several quarters to reach peak productivity, potentially delaying the expected positive impact on profitability and revenue acceleration in the near term. Myriad continues to anticipate modest headwinds to average selling prices (ASPs) over the longer term, which, combined with intensifying competition across its segments, could put pressure on gross margins and overall profitability, particularly as new tests like Precise MRD await broader reimbursement and market adoption.
- Bull Case
- Myriad Genetics is strategically focused on the Cancer Care Continuum, which is yielding strong results with hereditary cancer testing volumes growing 14% year-over-year, including a 16% increase in the unaffected population. This segment is the company's "profit engine," funding significant investments in new product development and commercial expansion. The company is executing on a robust pipeline, with the alpha launch of Precise MRD for breast cancer showing encouraging early feedback and planned expansion to colorectal and renal cancers in Q3 2026. The AI-enhanced Prolaris prostate cancer test launched in June, and the highly differentiated FirstGene prenatal test is on track for a full commercial launch in H2 2026, offering significant market expansion opportunities. The mental health business, GeneSight, also continues its strong performance, delivering 24% year-over-year revenue growth on 7% volume growth in Q1 2026, supported by improved reimbursement trends and a record high of over 39,000 ordering clinicians. The expansion of the commercial team by over 100 account executives is expected to accelerate growth across the portfolio in the second half of the year, with management reaffirming full-year 2026 financial guidance.
- More Compelling & Why
- Bear. Despite a low Price-to-Sales (P/S) ratio of approximately 0.6x-0.77x, which appears cheap relative to some industry peers, the company's Q1 2026 adjusted EBITDA loss of $5 million and adjusted EPS loss of $0.09 highlight significant near-term profitability challenges. The strongest argument for the bear case is the substantial execution risk associated with the ambitious H2 2026 ramp-up, particularly given the 15% year-over-year decline in the prenatal segment and the multi-quarter timeline for the new 100+ sales representatives to reach peak productivity. My view would flip to bullish if Myriad demonstrates a clear return to positive adjusted EBITDA in Q2 2026, alongside a significant and sustained improvement in prenatal revenue growth, indicating that strategic investments are translating into immediate and tangible financial results.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| AI-enhanced Prolaris Prostate Cancer Test Initial Adoption & Impact | This AI-enhanced test is expected to provide a step-up in value for prostate cancer management, improving Myriad's competitive position and driving volume/revenue growth for Prolaris. | Early commentary from management or clinicians on initial adoption, utility, and differentiation in Q2 2026 earnings call. Future quarterly reports for volume and revenue growth of Prolaris. The test launched on May 29, 2026 (excluding NY). | Bullish: Positive clinician feedback, early indications of market share gains or increased test utilization, and sustained mid-single-digit or higher volume/revenue growth for Prolaris. Bearish: Lukewarm clinician reception, lack of significant differentiation impacting adoption, or stagnation/decline in Prolaris volume/revenue. | Company's Q2 2026 earnings call and subsequent quarterly earnings releases (Form 10-Q). | Medical forums (e.g., Reddit r/oncology) for clinician discussions on new prostate cancer tests | Symphony Health: Prolaris test order volume |
| Precise MRD Commercial Expansion & MolDX Submissions Progress | Precise MRD is a key part of Myriad's Cancer Care Continuum strategy, with significant market potential. Successful expansion and timely MolDX submissions are critical for broader adoption and reimbursement. | Confirmation of MolDX submission for breast cancer in Q3 2026 and for colorectal and renal cancers by end of 2026. Early feedback on test utilization, customer experience, and turnaround times from the expanded sites (breast, colorectal, renal) following the June 2026 expansion. | Bullish: Timely MolDX submissions, positive early feedback on adoption and operational metrics from expanded sites, and increasing test utilization. Bearish: Delays in MolDX submissions, negative customer feedback, or slow adoption rates. | Company press releases, Q2 2026 and subsequent quarterly earnings calls (Form 10-Q). | Google Scholar/PubMed for new clinical publications on Precise MRD | Definitive Healthcare: Oncologist prescribing patterns for MRD tests |
| GeneSight Average Revenue Per Test (ASP) Trends | GeneSight's strong performance, driven by improved ASP, provides a stable foundation and enables strategic investments. Continued ASP improvement is crucial for overall profitability. | GeneSight revenue growth relative to volume growth in Q2 2026 and subsequent quarterly earnings reports. Management commentary on progress with health plans in biomarker law states and additional coverage opportunities. Q1 2026 ASP is considered a baseline. | Bullish: Continued sequential improvement in GeneSight ASP, or sustained high Y/Y revenue growth (e.g., above 20%) on moderate volume growth (e.g., mid-single digits). Bearish: Stagnation or decline in GeneSight ASP, or significant deceleration in revenue growth despite stable volume. | Company's Q2 2026 earnings call and subsequent quarterly earnings releases (Form 10-Q). | State legislative tracking for biomarker laws | Payer coverage databases (e.g., MMIT, Definitive Healthcare) for GeneSight |
| Hereditary Cancer Testing Volume Growth (Unaffected Population) | This segment is a primary revenue driver and 'profit engine' for Myriad, crucial for funding strategic investments. Sustained growth validates the focused sales strategy and market penetration. | Year-over-year volume growth rates in the unaffected population in Q2 2026 and subsequent quarterly earnings reports. Specific commentary on the impact of the newly dedicated sales force (started April 1st, 2026). | Bullish: Continued Y/Y volume growth in the mid-to-high teens (e.g., 15% or higher) or acceleration beyond Q1 2026 levels (16%). Bearish: Deceleration in Y/Y volume growth below 16%, suggesting challenges in commercial execution or market saturation. | Company's Q2 2026 earnings call and subsequent quarterly earnings releases (Form 10-Q). | Google Trends: "MyRisk hereditary cancer test" search volume | Thinknum: Sales representative hiring data for oncology/genomics |
| FirstGene Prenatal Test Full Commercial Launch & Adoption | FirstGene is a highly differentiated product expected to drive a return to positive growth in the prenatal segment, recapture market share, and expand the overall market. | Specific announcement of the full commercial launch date in H2 2026. Management commentary on initial customer wins, account reactivation, and volume trends in subsequent earnings calls. Updates on CONNECTOR study enrollment and assay performance. | Bullish: On-time full commercial launch in H2 2026, strong initial adoption rates, positive customer feedback, and clear signs of market share recapture or expansion. Bearish: Delays in full commercial launch, slow adoption, or continued weakness in the prenatal segment despite the launch. | Company press releases, Q2 2026 and subsequent quarterly earnings calls (Form 10-Q). | Google Trends: "FirstGene prenatal test" search volume | IQVIA: Prenatal test volume data |
Key Reported Metrics, Reratings Triggers & ResultsThis is Myriad's "profit engine" and a key driver for overall revenue growth and investment capacity. Continued strong growth validates the focused sales strate
No data for this section.
Key QuestionsWill the initial post-launch performance of FirstGene and the expanded availability of Precise MRD for breast, colorectal, and renal cancers, combined with the
Will the initial post-launch performance of FirstGene and the expanded availability of Precise MRD for breast, colorectal, and renal cancers, combined with the impact of the expanded commercial team, enable Myriad Genetics to meet its Q2 2026 revenue expectations and demonstrate a clear path to achieving its reaffirmed full-year guidance?
- Question 2
What will be the early market adoption rates, customer feedback, and initial volume contributions from the recently fully launched FirstGene prenatal screen and the expanded Precise MRD test across breast, colorectal, and renal cancers, indicating their potential to drive market share gains in the near term?
- Question 3
Given the Q1 adjusted EBITDA loss due to accelerated investments, can Myriad Genetics demonstrate effective operating expense management and progress towards its full-year adjusted EBITDA profitability target in its Q2 2026 results, validating the strategic investments for accelerated growth in the second half?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Prioritization of the Cancer Care Continuum**: Management is making significant investments in this area, including expanding commercial capabilities and increasing R&D spend on product development and clinical studies, as it is considered their business of highest importance. 2. **Strengthening the organization and improving execution**: This involves bringing in experienced leaders in oncology, genomics, and advanced diagnostics, implementing new decision-making processes, and simplifying the organizational structure to enhance agility and customer service. 3. **Successful launch and commercialization of new products**: Key launches include Precise MRD for breast cancer (with early access and planned expansion), the AI-enhanced Prolaris prostate cancer test, and FirstGene in prenatal health, which are expected to drive future growth and market share. | The overall tone of the call was cautiously optimistic. Management expressed confidence in achieving their full-year 2026 financial guidance, driven by strong performance in hereditary cancer testing and mental health (GeneSight), and anticipated improvements in the prenatal business. Key themes included significant strategic investments in the Cancer Care Continuum, particularly in commercial capabilities and R&D for new product launches like Precise MRD, AI-enhanced Prolaris, and FirstGene. While acknowledging challenges in the prenatal segment and the need to balance growth investments with profitability, management highlighted early positive feedback on new products and the impact of a reorganized, focused sales force. The call conveyed a sense of disciplined execution and a clear strategy for accelerating profitable growth in the coming quarters. | For Q4 2025: Cancer Care Continuum: 4% year-over-year growth (Hereditary cancer testing volume: 11% year-over-year; Prolaris prostate cancer test: 16% year-over-year growth in revenue). Prenatal Health: Stable year-over-year revenue. Mental Health (GeneSight): 9% year-over-year volume growth. | 1. **Revenue ramp through the back half of the year**: Analysts questioned the significant step-up in growth implied by the full-year guidance after a low single-digit first half. Management responded by reiterating confidence, citing continued strong hereditary cancer growth, solid GeneSight performance, expected improvement in the prenatal business, and contributions from the accelerated hiring of over 100 sales team members, particularly focused sales forces for unaffected hereditary cancer and prenatal. 2. **Balancing investment for new launches with maintaining adjusted EBITDA profitability**: Analysts asked how the company plans to manage the necessary investments for multiple upcoming product launches while adhering to its profitability targets. Management explained that it involves a well-crafted year with careful timing of investments, such as adding experienced sales team members for molecular cancer care, and balancing market activation with profitability goals. They emphasized that hereditary cancer is the 'profit engine' enabling these investments. 3. **Prenatal business performance and confidence in returning to growth**: Analysts noted the year-over-year deceleration in prenatal revenue despite sequential volume growth and questioned the reasonableness of expecting full-year growth and the resolution of internal issues. Management acknowledged the softer-than-expected volumes but expressed confidence due to the newly deployed prenatal-focused sales team, ongoing efforts to win back key accounts, and the highly differentiated FirstGene product, which is expected to drive both share recapture and market expansion. They also confirmed that internal operational issues related to order processing have been resolved. | Cancer Care Continuum: 4% year-over-year growth (Hereditary cancer testing volume: 14% year-over-year, with affected population growing 10% and unaffected population growing 16%; Prolaris prostate cancer test: mid-single-digit growth in both volume and revenue). Prenatal Health: 15% year-over-year decline. Mental Health (GeneSight): 24% year-over-year revenue growth on 7% volume growth. Total revenue: 2% year-over-year growth. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetics is making significant investments in the Cancer Care Continuum, including an expansion of commercial capabilities and increased R&D spend on product development and clinical studies. The company is driving strong volume growth for hereditary cancer testing in both affected (10%) and unaffected (16%) populations year-over-year. The addressable market for ultrasensitive MRD testing for breast and other cancers is expanding, with Myriad well-positioned to serve this growing opportunity. The company plans to expand commercial testing for Precise MRD for breast cancer in Q3 and is moving up the launch of Precise MRD for colorectal cancer and renal to a select set of customers into Q3. FirstGene is expected to expand clinical insight and grow the overall prenatal testing market, and the company believes it's an opportunity to expand the market as 2/3 of male partners are often unavailable for testing. Myriad continues to expand its GeneSight ordering provider base, reaching a record high of over 39,000 ordering clinicians in Q1. The hereditary cancer market is estimated at $7 billion and is less than 50% penetrated, offering significant growth room. | Myriad believes its MRD assay performance, including yield and turnaround time, is tracking within internal targets, which will allow it to be competitive with other on-market tests. The AI-enabled Prolaris test is differentiated and positions the company to compete more effectively in prostate cancer patient care. GeneSight holds the leading market share in the mental health testing market. FirstGene is highlighted as the first and only screen to simultaneously test for patient carrier status, fetal single gene, fetal chromosome, and fetal RHD status, delivered in a single integrated report, with an industry-leading 8-week gestational age and 14-day turnaround time, indicating a strong competitive advantage. Myriad also states that its MyRisk panel with 63 genes is the 'most relevant current' panel for hereditary cancer testing. | The transcript notes that over 75% of cancer care in the United States occurs in the community setting, and the market for incorporating MRD testing in community oncology is still in its formative stage. Improved reimbursement trends and payer coverage, aided by biomarker legislation, are positively impacting the mental health business. CIGNA updated its policy in April to cover expanded carrier screening panels, including Foresight Universal Plus, which is seen as an important step forward for the prenatal category. Myriad's engagement with health plans in biomarker law states has been productive, leading to sequential improvements in GeneSight's average revenue per test. The company anticipates modest headwinds to average selling prices (ASPs) over the longer term. | Myriad has a clear line of sight to achieving its goals of accelerated share gain and sustained profitable growth. The company expects sequential revenue growth in the low single digits in Q2, accelerating through the remaining quarters of 2026 as the expanded commercial team positively impacts the second half. Myriad is reaffirming its 2026 financial guidance. The AI-enhanced Prolaris prostate cancer test is on track to launch in June. The company plans to expand commercial testing for Precise MRD for breast cancer in Q3 and is moving up the launch of Precise MRD for colorectal cancer and renal to a select set of customers into Q3. FirstGene is on track for a full commercial launch in the second half of 2026. Myriad is investing $35 million over the next several years to strengthen commercial capabilities and support multiple upcoming launches, with an objective of faster awareness, adoption, and stronger return on investment. The company anticipates that ramping new territories for sales will take several quarters but is critical for long-term acceleration and profitable growth in the second half. | Diagnostics | The deep integration of AI and machine learning is a dominant broader theme, evolving from data analysis to influencing assay development and personalized treatment pathways. Myriad's upcoming AI-enhanced Prolaris prostate cancer test is an example of this trend. | We are reaffirming our 2026 financial guidance. hereditary cancer testing volume grew 14%, continuing to gain share. We remain on track for a full commercial launch in the second half of 2026, and we are investing ahead of that launch with confidence in FirstGene's ability to expand clinical insight and to grow the overall prenatal testing market. We continue to expand the ordering provider base, reaching over 39,000 ordering clinicians in the first quarter, which is a record high. The actions we've taken to sharpen focus, increase accountability and improve execution are translating into tangible momentum. | first quarter prenatal volume declined year-over-year. adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09 in Q1. First quarter adjusted EBITDA was a loss of $5 million, coming in below the near breakeven commentary we provided due to an acceleration of commercial growth investments. we continue to expect modest headwinds to ASPs over the longer term, consistent with our prior commentary. | Myriad has strengthened its organization by adding significant expertise at multiple levels, including a Chief Commercial Officer (Brian Donnelly), SVP of Product (Vishal Sikri), SVP of Oncology R&D (Dr. Hosein Kouros-Mehr), and other team members to operations, tech, sales, and marketing teams. The company made 'tough decisions that affected a number of our employees,' implying some workforce restructuring or reductions. Myriad expanded its sales team by over 100 account executives compared to last year, specifically adding meaningful field sales capacity in oncology to support new product introductions. Many of these new hires bring strong experience in the advanced diagnostics sector. The company is focused on improving sales productivity through better onboarding, targeting, and performance management, expecting new territories to take several quarters to reach peak productivity. Approximately two-thirds of the company's operating expenses are related to people. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetics is making significant investments in the Cancer Care Continuum, expanding commercial capabilities and increasing R&D spend on product development and clinical studies. The company is driving strong volume growth for hereditary cancer testing, with 10% growth in affected and 16% in unaffected populations year-over-year. The addressable market for ultrasensitive MRD testing for breast and other cancers is expanding, and Myriad is well-positioned to serve this growing opportunity. They are moving up the launch of Precise MRD for colorectal cancer and renal to a select set of customers into Q3. FirstGene is expected to expand clinical insight and grow the overall prenatal testing market, also seen as an opportunity to expand the market because two-thirds of male partners are often unavailable for testing. Myriad continues to expand its GeneSight ordering provider base, reaching a record high of over 39,000 ordering clinicians in Q1. The hereditary cancer market is estimated at $7 billion and is less than 50% penetrated, offering significant growth room. | Myriad believes its MRD assay performance, including yield and turnaround time, is tracking within internal targets, which will allow it to be competitive with other on-market tests. The AI-enabled Prolaris test is differentiated, combining AI, biomarker, germline, and genomic insights in a single offering, positioning the company to compete more effectively in prostate cancer patient care. GeneSight holds the leading market share in the mental health testing market. FirstGene is highlighted as the first and only screen to simultaneously test for patient carrier status, fetal single gene, fetal chromosome, and fetal RHD status, delivered in a single integrated report, with an industry-leading 8-week gestational age and 14-day turnaround time, indicating a strong competitive advantage. Myriad also states that its MyRisk panel with 63 genes is the 'most relevant current' panel for hereditary cancer testing. | Over 75% of cancer care in the United States occurs in the community setting, and the market for incorporating MRD testing in community oncology is still in its formative stage. Improved reimbursement trends and payer coverage, aided by biomarker legislation, are positively impacting the mental health business. CIGNA updated its policy in April to cover expanded carrier screening panels, including Foresight Universal Plus, which is seen as an important step forward for the prenatal category. Myriad's engagement with health plans in biomarker law states has been productive, leading to sequential improvements in GeneSight's average revenue per test. The company anticipates modest headwinds to average selling prices (ASPs) over the longer term. | Myriad has a clear line of sight to achieving its goals of accelerated share gain and sustained profitable growth. The company is reaffirming its 2026 financial guidance, expecting sequential revenue growth in the low single digits in Q2 and accelerating through the remaining quarters as the expanded commercial team positively impacts the second half. Myriad also reaffirmed its positive adjusted EBITDA target range. The AI-enhanced Prolaris prostate cancer test is on track to launch in June. The plan for MolDX submissions for Precise MRD remains to submit for breast cancer in Q3 and for colorectal and renal by the end of this year. Commercial testing for Precise MRD for breast cancer will expand in Q3 beyond current select community practices, and the launch of Precise MRD for colorectal cancer and renal is being moved up to a select set of customers in Q3. Full commercial launch for Precise MRD is expected in Q1 of 2027, with broader commercialization later this year. FirstGene is on track for a full commercial launch in the second half of 2026. Myriad is investing $35 million over the next several years to strengthen commercial capabilities and support multiple upcoming launches, with an objective of faster awareness, adoption, and stronger return on investment. Ramping new sales territories is expected to take several quarters but is critical for long-term acceleration and profitable growth in the second half. The company is committed to driving profitable growth and will manage annual operating expenses to grow at a slower rate than annual revenue. The AI-enabled Prolaris test is expected to be the first of multiple AI-enabled products brought to market in the coming years. | Diagnostics | The deep integration of AI and machine learning is a dominant broader theme, evolving from data analysis to influencing assay development and personalized treatment pathways, as exemplified by Myriad's upcoming AI-enhanced Prolaris prostate cancer test and plans for multiple AI-enabled products. | We are reaffirming our 2026 financial guidance. hereditary cancer testing volume grew 14%, continuing to gain share. We remain on track for a full commercial launch in the second half of 2026, and we are investing ahead of that launch with confidence in FirstGene's ability to expand clinical insight and to grow the overall prenatal testing market. We continue to expand the ordering provider base, reaching over 39,000 ordering clinicians in the first quarter, which is a record high. The actions we've taken to sharpen focus, increase accountability and improve execution are translating into tangible momentum. | first quarter prenatal volume declined year-over-year. adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09 in Q1. First quarter adjusted EBITDA was a loss of $5 million, coming in below the near breakeven commentary we provided due to an acceleration of commercial growth investments. we continue to expect modest headwinds to ASPs over the longer term, consistent with our prior commentary. | Myriad has strengthened its organization with leaders experienced in oncology, genomics, and advanced diagnostics, adding significant expertise across operations, tech, sales, and marketing teams, including a new CCO, SVP of Product, and SVP of Oncology R&D. The company simplified its organizational structure and removed layers, which required making tough decisions that affected a number of employees. Myriad expanded its sales team by over 100 account executives compared to last year, adding meaningful field sales capacity, particularly in oncology, with many new hires bringing strong experience in the advanced diagnostics sector. These 100 new hires were accelerated and are currently undergoing training. The company has focused its sales forces, with dedicated teams for unaffected hereditary cancer and prenatal products. The vast majority of the 100 new hires are related to the Cancer Care Continuum, including a meaningful number of individuals with molecular backgrounds for the MRD space. Ramping new territories for these sales representatives is expected to take several quarters to reach peak productivity. Approximately two-thirds of the company's operating expenses are related to people. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| MYGN_c65d39f3 | into Q3 | 2026-07-01 | 2026-09-30 | Initial launch of Precise MRD for colorectal and renal cancers to a select set of customers. | This accelerated launch reflects strong customer interest and allows Myriad to gain early insights into commercialization across multiple indications, potentially expanding its market opportunity. | Ticker | 2026-05-05 | earnings_transcript |